Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
1
20.0%
招募中
4
80.0%
暂无批准数据
- Curebound Cancer Challenge returns August 1, 2026, at UC San Diego, having raised $24.5 million since launch with 100% of participant-raised dollars funding collaborative cancer research. - Grant applications surged 21% year-over-year to a record 186 letters of intent from 69 teams, reflecting an extraordinary pipeline of innovative cancer research awaiting funding. - A 2024 Discovery Grant of $250,000 to Dr. Hojun Li for pediatric leukemia prevention research helped secure nearly $8.6 million in follow-on funding, a 34-fold return. - San Diego's ecosystem includes three NCI-Designated Cancer Centers — UC San Diego Moores Cancer Center, Salk Institute, and Sanford Burnham Prebys — forming a uniquely collaborative research hub.
- Bristol Myers Squibb has entered an $850 million collaboration with Janux Therapeutics to develop novel tumor-activated cancer therapeutics targeting solid tumor antigens. - The partnership leverages Janux's proprietary platform technology designed to reduce systemic toxicities commonly associated with T cell engagers by activating only within the tumor microenvironment. - Janux will handle preclinical development through IND submission, while BMS will lead clinical development and global commercialization of the undisclosed solid tumor therapeutic. - The deal includes $50 million in upfront and near-term payments, with up to $800 million in additional milestones plus tiered royalties on global sales.
- Janux Therapeutics appointed William Go, M.D., Ph.D., as Chief Medical Officer effective January 26, 2026, bringing over 20 years of hematology and oncology experience to lead the company's expanding clinical pipeline. - Dr. Go previously served as CMO at A2 Biotherapeutics and led the pivotal ZUMA-1 trial at Kite Pharma that supported FDA approval of YESCARTA, the first CAR T-cell therapy for large B-cell lymphoma. - The appointment comes as Janux advances its TRACTr platform with JANX008 completing Phase 1a dose-escalation and initiating expansion cohorts for multiple solid tumor indications. - Janux's pipeline includes two clinical-stage TRACTr candidates targeting PSMA for prostate cancer and EGFR for various solid tumors, along with additional programs in development.
- JANX007, a first-in-class tumor-activated T-cell engager targeting PSMA, achieved a 73% PSA50 response rate and 30% objective response rate in 109 patients with metastatic castration-resistant prostate cancer. - The investigational therapy demonstrated durable responses with median radiographic progression-free survival ranging from 7.9 to 8.9 months, with biweekly dosing showing favorable outcomes. - Cytokine release syndrome occurred in 96% of patients but was predominantly low-grade and manageable, with 88% experiencing grade 1-2 events that typically resolved within one day. - Early data from taxane-naive patients showed particularly encouraging results, with 100% achieving PSA50 reduction and 63% achieving PSA90 reduction in the first evaluable cohort.
- Janux Therapeutics received a $10 million milestone payment from Merck following the dosing of the first patient in their TRACTr collaboration for cancer immunotherapy development. - The milestone validates Janux's modular TRACTr platform technology, which is designed to overcome limitations of traditional T-cell engagers by activating only within the tumor microenvironment. - Janux currently has two TRACTr candidates in Phase 1 clinical trials: JANX007 targeting PSMA and JANX008 targeting EGFR, with potential for additional development and commercial milestone payments. - Despite the positive development, the company continues to face funding challenges due to accelerating operating losses and the need to manage large cash burn rates.
- Janux Therapeutics showcased its expanded immunotherapy pipeline at R&D Day, highlighting three proprietary platforms: TRACTr, TRACIr, and the novel ARM platform targeting autoimmune diseases. - The company's CD19-ARM demonstrated rapid, deep B-cell depletion with prolonged memory B cell reset in non-human primates while maintaining a large safety window, positioning it for first-in-human trials in H1 2026. - Clinical programs JANX007 and JANX008 continue enrollment with data updates expected in H2 2025, while new TROP2-TRACTr and PSMA-TRACIr programs advance toward clinical development. - The company reported $996.0 million in cash and investments as of Q2 2025, providing substantial runway for its expanding development programs.
- DelveInsight's assessment reveals over 50 companies are actively developing 60+ advanced renal cell carcinoma therapies across various clinical phases. - Recent regulatory milestones include Innovent Biologics and HUTCHMED seeking approval for their sintilimab-fruquintinib combination following successful Phase II/III trial results. - Emerging therapies span multiple mechanisms including checkpoint inhibitors, antibody-drug conjugates, and targeted small molecules, with notable candidates like OATD-02, DS-6000a, and NKT2152 advancing through clinical development. - The pipeline demonstrates significant diversity in therapeutic approaches, with treatments categorized across oral, parenteral, and intravenous routes of administration.
- Janux Therapeutics has initiated Phase 1b expansion studies of JANX007 in taxane-naïve metastatic castration-resistant prostate cancer patients, marking progression to earlier treatment lines. - Updated data from Phase 1a trials showed median radiographic progression-free survival of 7.5 months across all patients, with improved outcomes of 7.9 months in higher-dose cohorts. - The company plans three additional Phase 1b studies exploring JANX007 as both monotherapy and in combination therapy, with further clinical updates expected in the second half of 2025.
• Morgan Stanley highlights Janux Therapeutics' positive Phase 1a data for JANX007 in metastatic castration-resistant prostate cancer. • The analyst suggests these findings provide a favorable readthrough for Vir Biotechnology's masked T-cell engager (TCE) pipeline. • Vir Biotechnology is anticipated to release initial Phase 1 monotherapy data from VIR-5818 and VIR-5500 in the first quarter of 2025. • Morgan Stanley maintains an Equal Weight rating on Vir shares, setting a price target of $10.
- Janux Therapeutics' JANX007 demonstrated significant PSA reduction in heavily pre-treated metastatic castration-resistant prostate cancer patients. - The Phase 1a study showed a favorable safety profile with mostly mild to moderate treatment-related side effects, including cytokine release syndrome. - Analysts are optimistic about JANX007's potential, citing its efficacy and safety profile, and have raised peak sales estimates. - Janux has selected doses for Phase 1b expansion trials in patients with less advanced disease who have not received Pluvicto, with updated results expected next year.
